World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

Cision PR Newswire by Cision PR Newswire
June 5, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney disease

ZHUBEI CITY, Taiwan and RALEIGH, N.C., June 5, 2026 /PRNewswire/ — Bio Preventive Medicine Corp. and Precision Diabetes, Inc. today announced presentation of a Late-Breaking Abstract at the American Diabetes Association (ADA) 86th Scientific Sessions highlighting new findings from the landmark CREDENCE trial demonstrating that DNlite™ independently predicts adverse renal outcomes beyond conventional renal biomarkers, including albuminuria and eGFR, in patients with type 2 diabetes and chronic kidney disease (CKD).


(PRNewsfoto/Precision Diabetes, Inc.)

DNlite™ measures urinary post-translationally modified Fetuin-A (uPTM-FetA), a novel biomarker associated with kidney stress, inflammation, metabolic dysregulation, and progressive renal injury. The assay is designed to help identify patients with diabetic kidney disease who may remain at elevated risk for progression beyond what is fully captured by conventional renal biomarkers alone.

CREDENCE was a landmark international renal outcomes trial that helped establish SGLT2 inhibitors as a foundational therapy for diabetic kidney disease. Despite major therapeutic advances, many patients with type 2 diabetes and CKD continue to experience progressive renal decline and remain difficult to risk stratify using conventional clinical measures alone.

The new analysis suggests the DNlite™ assay may help identify patients at persistently elevated renal risk earlier in the disease process and beyond conventional measures of kidney disease severity.

The presentation, titled “Urinary Post-Translationally Modified Fetuin-A Predicts Renal Outcomes Independent of Albuminuria and eGFR in Type 2 Diabetes and CKD: CREDENCE Analysis,” evaluated baseline DNlite™ assay results in 2,429 participants from the CREDENCE trial, including both placebo-treated and canagliflozin-treated participants.

Key findings from the analysis include:

  • DNlite™ independently predicted adverse renal outcomes after multivariable adjustment
  • Renal risk increased progressively across uPTM-FetA tertiles and quartiles
  • Kaplan–Meier analyses demonstrated significant risk stratification across both placebo and treatment arms
  • The assay provided prognostic information beyond traditional renal markers including UACR and eGFR

“DNlite™ reflects a unique aspect of kidney stress biology that is not fully captured by traditional renal markers alone,” said Karen Tseng, CEO of Bio Preventive Medicine Corp. “The consistency of these findings across both untreated and treated populations strengthens our confidence in the clinical relevance of this biomarker platform.”

“Residual renal risk remains a major challenge in patients with type 2 diabetes and CKD, even in the era of SGLT2 inhibitor therapy,” said Ele Ferrannini, Emeritus Investigator of the National Research Institute of Clinical Physiology. “This analysis demonstrates that the DNlite assay provides independent prognostic information beyond conventional clinical parameters and may help refine renal risk assessment in this population.”

The companies believe the DNlite™ assay represents a promising next-generation biomarker approach for improving early DKD risk stratification and identifying residual renal risk in high-risk patients.

Additional Statement: Professor Ele Ferrannini, a renowned leader in diabetes and metabolic disease research and senior author on the study, passed away shortly before the presentation of these findings at the ADA Scientific Sessions. Precision Diabetes and Bio Preventive Medicine are honored to recognize his longstanding scientific contributions and collaboration on this work.

About Bio Preventive Medicine Corp.

Bio Preventive Medicine Corp. is a clinical-stage biotechnology company focused on advancing precision diagnostics for kidney disease and chronic metabolic disorders. The company develops biomarker-driven solutions designed to enable earlier disease detection, improved renal risk stratification, and more personalized patient management. Bio Preventive Medicine is advancing diagnostic platforms spanning in vitro diagnostics (IVDs) and laboratory-developed testing services to address unmet clinical needs in renal and chronic disease care.

About Precision Diabetes, Inc.

Precision Diabetes, Inc. (Raleigh, North Carolina) is an emerging leader in enabling precision medicine for diabetes by using novel diabetes biomarkers and algorithms. The company’s mission is to revolutionize the diagnostic assessment of diabetes by providing a spectrum of unique diabetes tests, spanning the risk of developing diabetes to developing diabetes complications.

Media Contact:
Eric Button
Ebutton@precisiondiabetesinc.com
919-280-3482

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-preventive-medicine-and-precision-diabetes-announce-ada-late-breaking-presentation-highlighting-dnlite-in-landmark-credence-trial-302781961.html

SOURCE Precision Diabetes, Inc.

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • CPP Investments and Ontario Teachers’ to join Nordic Capital as owners of Cary Group to support its continued international expansion and long-term development

    0 shares
    Share 0 Tweet 0
  • 17th Caixin Summit Opens in Beijing Under the Theme “Challenges Abound, Growth Answers”

    0 shares
    Share 0 Tweet 0
  • VT Markets Integrates Global Market Insights Directly into ChatGPT and Claude

    0 shares
    Share 0 Tweet 0
  • 91% of Capital Markets Respondents Want AI to Deliver Greater Accuracy and Fewer Errors

    0 shares
    Share 0 Tweet 0
  • What price data reveals about the fastest-changing areas

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler